Showing results (131-140 of 6,269) with videos related to

Sort By:
Pageof 627
Diabetes, Obesity & Metabolism|December 8, 2015
Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate dietR Nishimura, H Omiya, K Sugio, et al.
Diabetes, Obesity & Metabolism|December 8, 2015
Glucagon-like peptide-1 receptor agonist exenatide has no acute effect on MRI-measured exocrine pancreatic function in patients with type 2 diabetes: a randomized trialM M Smits, L Tonneijck, M H A Muskiet, et al.
Diabetes, Obesity & Metabolism|December 15, 2015
Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta-analysis of the liraglutide phase III clinical trial programmeE Montanya, V Fonseca, S Colagiuri, et al.
Diabetes, Obesity & Metabolism|May 2, 2022
Real-world outcomes of addition of insulin glargine 300 U/mL (Gla-300) to glucagon-like peptide-1 receptor agonist (GLP-1 RA) therapy in people with type 2 diabetes: The DELIVER-G studyTimothy S Bailey, Jasvinder Gill, Merwyn Jones S, et al.
Diabetes, Obesity & Metabolism|May 2, 2022
Combination therapy with exenatide decreases the dapagliflozin-induced changes in brain responses to anticipation and consumption of palatable food in patients with type 2 diabetes: A randomized controlled trialCharlotte C van Ruiten, Dick J Veltman, Madelief Wijdeveld, et al.
Diabetes, Obesity & Metabolism|July 15, 2022
Effects of 26 weeks of treatment with empagliflozin versus glimepiride on the myocardial glucose metabolic rate in patients with type 2 diabetes: The randomized, open-label, crossover, active-comparator FIORE trialElena Succurro, Patrizia Vizza, Annalisa Papa, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, slows the progression of renal complications through the suppression of renal inflammation, endoplasmic reticulum stress and apoptosis in prediabetic ratsKrit Jaikumkao, Anchalee Pongchaidecha, Nuttawud Chueakula, et al.
Diabetes, Obesity & Metabolism|June 21, 2018
Low incidence of gastrointestinal adverse events over time with a fixed-ratio combination of insulin glargine and lixisenatide versus lixisenatide aloneJennifer M Trujillo, Michelle Roberts, Terry Dex, et al.
Diabetes, Obesity & Metabolism|June 23, 2018
Non-adherence to basal insulin among patients with type 2 diabetes in a US managed care population: Results from a patient surveyJudith J Stephenson, Amit D Raval, David M Kern, et al.
Diabetes, Obesity & Metabolism|September 12, 2018
Intranasal oxytocin fails to acutely improve glucose metabolism in obese menSwantje Brede, Sebastian Fehr, Chiara Dalla-Man, et al.
Pageof 627